Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
844.2 DKK | -1.77% | -0.68% | +9.35% |
May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 | |
May. 07 | European shares hit one-month high as earnings take centre stage | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.35% | 28.03B | |
-32.59% | 3.01B | |
+25.19% | 2.52B | |
-20.16% | 2.43B | |
+3.17% | 2.16B | |
+25.56% | 2.06B | |
-10.76% | 1.96B | |
+21.43% | 1.33B | |
+27.03% | 1.32B | |
-2.32% | 1.25B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24